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Abstract
Introduction: The aim of this study is to present a model for assuring the quality of a large number of glucometers being used in a high-volume 
hospital clinical setting.
Materials and methods: Internal quality-control samples and blood samples from two patients were used to determine the accuracy of 83 gluco-
meters used at our hospital. On each glucometer three levels of control were used for glucose concentrations determination. In addition, the diffe-
rence between the results from patient samples obtained with the glucometers and the hexokinase reference method were compared. The differen-
ces were assessed based on the International Organization for Standardization (ISO 15197) standards.
Results: The glucose concentrations were as follows: 2.51 ± 0.34 mmol/L for the hypo-control samples; 5.12 ± 0.32 mmol/L for the low-control 
samples; and 16.11 ± 1.03 mmol/L for high-control samples. All results were within the expected ranges. For Patient I, the result with the first group 
of 52 glucometers was 11.56 ± 0.5 mmol/L, while the result for Patient II with the second group of 31 glucometers was 10.52 ± 0.62 mmol/L. All 
data points of the study complied with the requirements of the Clarke error grid.
Conclusion: All quality-control and comparison assay results were appropriate for evaluating glucometers used in a high-volume hospital setting. 
The method used in this study can be suggested as a model for laboratory managers, especially in similar high-volume hospitals.
Key words: point-of-care testing (POCT); quality management program for glucometers; high-volume clinical setting; ISO 15197
Received: November 17, 2015 Accepted: March 06, 2016
A model for managing and monitoring the quality of glucometers used in a 
high-volume clinical setting
Güzin Aykal*, Ayşenur Yegin, Özgür Tekeli, Necat Yilmaz




Point-of-care testing (POCT) is widely used in the 
management of diabetes by health care profes-
sionals in clinical settings, as well as by patients 
themselves (1). Glucometers, portable glucose an-
alysers, are POCT devices recommended by the 
American Diabetes Association (ADA) for self-
monitoring at home, in the field, or in clinical set-
tings (2). With the wide availability of various glu-
cometers, there are persistent attempts to im-
prove the accuracy and precision of glucometer 
readings, in order to match laboratory values for 
blood glucose (3). While there have been dramatic 
improvements in performance regarding blood-
sample volume and analysis time, only modest im-
provements in accuracy have been reported since 
1989 (2). Due to significant variation among glu-
cometer devices, groups such as the International 
Organization for Standardization (ISO) have devel-
oped performance guidelines. System accuracy 
criteria for verification of analytical performance 
capability is established in the first edition of Inter-
national Standards, ISO 15197:2003, which states 
that the acceptable system accuracy should be ± 
0.83 mmol/L at glucose concentrations of < 4.2 
mmol/L, and ± 20% at glucose concentrations of ≥ 
4.2 mmol/L (4). However, the second edition, ISO 
15197:2013, includes stricter criteria for accuracy, 
stipulating that 95% of measured glucose values 
shall fall within either ± 0.83 mmol/L of the aver-
age measured values of the reference measure-
ment procedure at glucose concentrations of < 
5.55 mmol/L, or within ± 15% at glucose concen-
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trations of ≥ 5.55 mmol/L (5). In addition, the Hos-
pital Services Quality Standards (HSQS), published 
in 2011 by the Turkish Republic Ministry of Health, 
identifies procedures for calibration and quality-
control testing, as well as quality-management re-
quirements for POCT devices in general (6). How-
ever, neither the ISO nor the HSQS guidelines pro-
vide any detailed information for monitoring glu-
cometers in hospital settings.
Some recent studies on the subject have either 
evaluated the performance of a recently introduced 
glucometer or compared the accuracy and preci-
sion of one glucometer to another (2,7-10). Few 
studies have precisely quantified the accuracy, reli-
ability and bias of glucometers that are to be used 
in a research laboratory (2). However, to our knowl-
edge, there is no study in the literature providing 
details of how a laboratory should check these pro-
cesses and devices in practice. Therefore, the aim of 
this study was to present a routine quality-manage-
ment program for managing and monitoring the 
quality of a large number of glucometers used in 
the clinical setting of a high-volume hospital.
Materials and methods
Subjects 
This was a cross-sectional quality-control study 
that was performed to monitor the quality of 83 
glucometers used at Antalya Education and Re-
search Hospital, a high-volume tertiary referral 
centre. The study was conducted in the centre’s 
Clinical Chemistry Laboratory by laboratory tech-
nicians under the supervision of a laboratory ex-
pert in February 2015. The study was performed in 
two sessions on the same day; 52 glucometers 
were collected and tested in the laboratory in the 
morning, and the remaining 31 were collected and 
tested in the afternoon, so that patients’ glucose 
levels could continue to be monitored in the vari-
ous hospital departments.
Internal quality-control samples, supplied by the 
glucometer manufacturer, and blood samples 
from two patients, Patient I and Patient II, were 
used to determine the accuracy of the glucome-
ters. Three levels of internal quality-control materi-
als were measured twice on each glucometer. Du-
plicate measurements from each instrument were 
averaged, and these mean values were used for 
data analysis. Both of the patients had high glu-
cose levels and were inpatients in the endocrinol-
ogy unit; each patient had been evaluated and di-
agnosed with diabetes by an endocrinologist. 
Their blood glucose was measured with both the 
glucose assay and the glucometers, for the quality 
management of the glucometers used throughout 
the hospital, as indicated in the HSQS. Patient I, a 
54-year-old male, had a haemoglobin of 152 g/L 
and a haematocrit of 0.440 L/L. Patient II was a 
42-year-old male with a haemoglobin level of 162 
g/L  and a haematocrit of 0.482 L/L. Both patients 
provided informed consent for venipuncture, in 
accordance with the forms of HSQS. Two separate 
tubes of whole blood were obtained from each 
patient in the fasting state, to be used in one ses-
sion of the study. The samples were collected by 
venipuncture in K3 EDTA-containing tubes for anti-
coagulation (Isotherm 2 mL, lot 140720, REF IST412, 
Weihai Hongyu Medical Devices Co., Shandong, 
China; 1.8 mg/mL K3EDTA). 
One of the whole-blood samples from Patient I 
was centrifuged (10 min, 900 x g), and the separat-
ed plasma was loaded on the analyser (AU5800; 
Beckman Coulter Inc., Brea, CA, USA). Duplicate re-
sults were obtained for each sample. The second 
tube was transferred to the working area as soon 
as possible to obtain the glucometer assay results. 
Laboratory staff performed the assay using the 
whole blood, and this sample was used for all 52 
glucometers during the morning session of the 
study. Patient II was venipunctured for the second 
session of the study, and these samples were used 
for the second group of 31 glucometers, for which 
the same procedures were followed.
Methods
Test procedures were performed by laboratory 
personnel who were well-trained in the limitations 
of the test systems, the manufacturer’s instruc-
tions, the safety practices, and the study protocol. 
Measurement procedures were carried out under 
controlled temperature (21–24 °C) and humidity 
(31–57%).
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The POCT glucometers (Rheamed RA1103; 
Rheamed Biotechnology Co., Changhua, Taiwan) 
use an electrochemical detection technique and 
dry reagent strip technology, with the glucose oxi-
dase method. The system provides quantitative 
measurements of glucose concentrations from 
1.1–33.3 mmol/L.
Three levels of control solutions specifically de-
signed for use with the device were used to check 
the performance of each glucometer, the test 
strips and the testing technique. The control meas-
urements for the devices were determined with 
three levels of control materials, and the results 
were calculated with two replicates. Rheamed 
control solutions for hypo control (range 1.83–3.49 
mmol/L; lot MH1901), low control (range 4.44–6.66 
mmol/L; lot NC0601), and high control (range 
16.03–24.03 mmol/L; lot NL0301) were used. Refer-
ence method measurements of glucose in patient 
plasma were performed with an enzymatic UV 
test, the hexokinase method (lot 6353, Beckman 
Coulter Inc., Brea, CA, USA) on a Beckman Coulter 
AU5800 analyzer. The test is linear within a con-
centration range of 0.6–45.0 mmol/L for serum, 
plasma, hemolysate and CSF.
Statistical analysis
The reproducibility and the deviation of the results 
from the average were calculated with the coeffi-
cient of variation [CV% = (standard deviation / 
mean) × 100]. Bland–Altman percentage plots 
were used to determine a percentage deviation of 
the average, independent of the concentration 
range. The difference plot, namely the Bland–Alt-
man plot, is the recommended approach for de-
termining system accuracy because statistical as-
sumptions are minimal, and the percentage of the 
data points meeting the system accuracy perfor-
mance criteria, as well as the estimating bias, are 
easily calculated (5). Also, a Clarke grid and consen-
sus grid plots were used to evaluate the clinical 
significance of inaccuracies in the measurements 
of blood glucose concentrations. The Clarke Error 
Grid Analysis compares the clinical significance of 
the bias between blood glucose system results 
and lab reference results. For the analysis, data 
points are assigned to five zones (A–E) on the error 
grid. The results, or data points, falling into zones 
A and B are defined as clinically acceptable, for 
which any observed bias from lab results would 
not lead to treatment decisions that may put a pa-
tient at risk. As the bias, or difference, increases 
(zones C, D and E), there is a greater risk of under-
treating or over-treating a patient based on the re-
sults. Statistical testing was performed with SPSS 
version 18.0 (IBM Corporation, New York, US) (11,12). 
The paired glucose measurements obtained from 
the POCT devices and the Beckman Coulter 
AU5800 were compared by linear regression anal-
ysis and presented as Bland–Altman plots (4,5). 
Results
Mean glucose concentrations of the control and 
patient samples were determined with 83 glucom-
eters and the standard deviations (SDs) and coeffi-
cients of variation (CV%) are presented in Tables 1 
and 2. Table 1 shows the results of the three con-
trol samples for glucose concentrations measured 
on all 83 glucometers, within the indicated inter-
vals. The mean values for the control samples were 
as follows: 2.51 mmol/L for the hypo-control sam-
ples, 5.12 mmol/L for the low-control samples and 
18.11 mmol/L for the high-control samples. Table 2 
shows the results of the patient samples for glu-
cose concentrations measured in two sessions. 
Figures 1, 2 and 3 present the results of all of the 
POCT control measurements shown in the Bland–
Altman diagrams. The figures show that all results 
were within the reference ranges for each control 
sample.
To observe the quality control results of the refer-
ence analyser (Beckman Coulter AU5800), internal 
quality-control glucose measurements were per-
formed on the same day, with results of 5.77 
mmol/L for the low-level control sample (refer-
ence range 4.66–6.44 mmol/L) and 13 mmol/L for 
the high-level control sample (reference range 
10.61–16.5 mmol/L). The within-run precision and 
total precision for the hexokinase method are 
each less than 3%. External quality-control glucose 
measurements with the analyzer were within the 
appropriate range in February 2015. The plasma 
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QC Material Expected QC range (mmol/L)
Glucose measurements
Mean 
(mmol/L) SD CV (%)
Hypo-level 1.83–3.49 2.51 0.34 13.8
Low-level 4.44–6.66 5.12 0.32 6.3
High-level 16.03–24.03 18.11 1.03 5.7





(mmol/L) SD CV (%)
Patient 1 11.56 0.5 4.4
Patient 2 10.52 0.62 5.98
SD – standard deviation, CV – coefficient of variation.
Table 1. Mean glucose concentrations of control samples on 
glucometers investigated.
Table 2. Mean glucose concentrations for whole-blood sam-
ples on glucometers investigated.
Figure 3. High-control measurements.
The Bland–Altman diagram shows that control sample results 
of all glucometers tested are within the expected range of the 
high-control sample. Dashed lines – expected range of the 
high-control sample. Solid line – mean glucose concentration 
obtained by testing high-control samples.  
Figure 1. Hypo-control measurements. 
The Bland–Altman diagram shows that control sample results 
of all glucometers tested are within the expected range of the 
hypo-control sample. Dashed lines – expected range of the hy-
po-control sample. Solid line – mean glucose concentration ob-
tained by testing hypo-control samples. 
Figure 2. Low-control measurements.
The Bland–Altman diagram shows that control sample results 
of all glucometers tested are within the expected range of the 
low-control sample. Dashed lines – expected range of the low-
control sample. Solid line – mean glucose concentration ob-
tained by testing low-control samples.  























































































glucose level of Patient I was determined as 12.05 
mmol/L, and of Patient II was 10.33 mmol/L.
The Clarke Error Grid Analysis was used for the ac-
curacy quantification of POCT data against plasma 
glucose values from the Beckman Coulter AU5800. 
This analysis partitions the total blood glucose 
range into zones, based in the effects of glucose 
variations during diabetes treatment (3). The zones 
are as follows: 
1. Zone A: no effect on clinical action
2. Zone B: altered clinical action – little or no ef-
fect on clinical outcome
3. Zone C: altered clinical action – likely to affect 
clinical outcome
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4. Zone D: altered clinical action – could have sig-
nificant medical risk
5. Zone E: altered clinical action – could have dan-
gerous consequences (5).
Figure 4 shows that all data points of the study fall 
into Zone A.
The Bland–Altman percentage plot is presented in 
Figure 5 for plasma measurements against POCT 
values. The figure illustrates the comparison of the 
ISO 15197:2003 bias limits compared to the ISO 
15197:2013 criteria for accuracy, and shows that all 
of the POCT results were within the bias limits for 
ISO 15197:2003, but eight were outside the limits 
for ISO 15197:2013.
Figure 5. Difference plot of measured values of 83 glucometers. 
This modified Bland–Altman plot gives superimposed tolerance bands for both ISO 15197:2003 and ISO 15197:2013 criteria. Solid 
lines – accuracy criteria of ISO 15197:2013; dashed lines – accuracy criteria of ISO 15197:2003. The horizontal black dashed line repre-
sents the mean bias, while the horizontal grey dashed lines are the limits of agreement (bias ± 1.96 SD).
Figure 4. Clarke error grid analysis for results of patients obtained with each glucometer versus the hexokinase method. 
Zone A – no effect on clinical action. Zone B – altered clinical action, little or no effect on clinical outcome. Zone C – altered clinical 
action, likely to affect clinical outcome. Zone D – altered clinical action, could have significant medical risk. Zone E – altered clinical 
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Discussion
The Bland–Altman diagrams show that the control 
sample results of 83 glucometer devices used in 
the hospital were within the expected range of 
the quality-control samples. To our knowledge, 
this is the first study reporting a model for com-
paring the results of a patient sample assayed on 
all of the glucometers used in a high-volume hos-
pital, by analysing the reference method results of 
the same blood sample on the same day. ISO 
15197:2013 recommends Bland–Altman and Clarke 
grid statistical methods for the data analysis of 
glucose measurements using capillary blood and 
plasma samples (5). The guidelines also state that 
99% of all results must be in zones A and B of the 
consensus error grid (5). All data points of the 
study complied with the requirements of the 
Clarke error grid, representing accurate and ac-
ceptable glucose results. The Bland–Altman plot 
shows the absolute differences between the glu-
cometer measurement results and the comparison 
measurement results. All of the POCT results were 
within the bias limits for ISO 15197:2003. However, 
results obtained with eight glucometers were out-
side the bias limits for ISO 15197:2013. For POCT 
systems, the accuracy criteria of ISO 15197:2003, 
which specify requirements for glucose-monitor-
ing systems intended for self-testing by laypersons 
for the management of diabetes mellitus, are in-
ternationally accepted. In the recently published 
revision ISO 15197:2013, for which mandatory com-
pliance is recommended after a 36-month transi-
tion period, the criteria for system accuracy are 
more stringent (4,6). The ISO’s most recent stand-
ards provide a refinement of the performance re-
quirements defined in the ISO 15197:2003 guide-
lines (1). Freckmann et al. (1) pointed out that sys-
tem accuracy was evaluated in under-standard-
ized conditions, following the ISO Standard 
15197:2003. They suggested that self-monitoring 
of blood glucose systems can achieve system ac-
curacy that is comparable with professional-use 
systems when measurements are performed by 
trained personnel in a standardized and controlled 
setting. Consequently, it was decided that the glu-
cometers (N = 8) with results outside the limits in 
this study were out of order, and they were re-
placed with new glucometers that complied with 
accuracy criteria.
Wehmeier et al. (13) suggested that regular moni-
toring of the analytical performance of POCT re-
mains of utmost importance. This may involve dai-
ly internal quality-control procedures (if used for 
patient samples) with the control material provid-
ed by the manufacturer to check the precision, as 
well as frequent comparisons with the traceable 
measurement procedure. As part of the ongoing 
quality-control programme in the central labora-
tory, monthly comparisons are recommended in 
order to monitor the reliability of measurements 
and to harmonize results from POCT with the 
traceable measurement procedure (13).  
Many countries have created their own policies, 
procedures or standards that control the use of 
POCT, in particular any essential requirements and 
quality-management issues (14). HSQS, published 
in 2011 by the Turkish Republic Ministry of Health, 
states that POCT devices should be used near or at 
the site where care is delivered to patients. These 
standards define the scope of POCT quality con-
trol, and consistent supervision is required by a bi-
ochemistry expert. In line with these standards, 
routine operational procedures are implemented 
in our hospital for managing the quality control of 
glucometers. According to these procedures, each 
clinic should check the devices daily using the con-
trol samples provided by the manufacturer, and 
the results should be documented. However, the 
HSQS does not define when and how the labora-
tory expert should monitor the devices and man-
age the quality control of all glucometers in a 
high-volume hospital. Therefore, in this study, a 
scheme to be followed for the monthly routine 
management of glucometers has been developed 
by a laboratory expert. Glucometers used in all of 
the hospital’s clinics should be delivered to the bi-
ochemistry laboratory every month, so that inter-
nal quality-control samples (at least two levels) 
provided by the manufacturer may be measured 
and recorded. In the interim, the glucose concen-
tration of a patient sample determined by a clini-
cal chemistry analyzer using the hexokinase meth-
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od should be used for comparison with the results 
obtained by all the devices. The results should 
then be documented, as defined in ISO 15197:2013. 
The POCT biochemistry specialist should use the 
comparison methods and evaluate the results, and 
the glucometer should be replaced with an appro-
priate, pre-tested device if the measurements are 
not adequate.
All quality-control and comparison assay results 
obtained in this study were appropriate for evalu-
ating the glucometers used in a hospital with a 
high-volume clinical setting. The method used in 
this study can be suggested as a model for labora-
tory managers, especially in similar high-volume 
hospitals. 
This study had some limitations. One of the most 
difficult issues in gathering all of the glucometers 
in the laboratory was the management of patient 
safety. The laboratory could not ask for all the glu-
cometers of certain departments at the same time, 
especially in units where patients’ glucose levels 
should be monitored continuously, such as the in-
tensive care unit and endocrine services, or emer-
gency services, where a new patient could arrive 
at any moment. Therefore, the laboratory crew 
had to collect the glucometers and analyse the re-
sults in two sessions. Another challenge in our 
study was comparing the results of glucometer 
measurements with the reference method results. 
ISO 15197:2013 recommends comparing capillary 
blood samples with plasma samples. However, it 
would be impossible to obtain 83 capillary blood 
samples all at once. A comparison study done with 
the same sample would be more effective than us-
ing different patient samples. Consequently, we 
decided to use whole blood with EDTA to obtain 
both the glucometer measurement results and the 
reference method results, instead of capillary 
whole-blood samples, due to the similarity and 
closeness.
In addition, it should be mentioned that besides 
routine monthly checks, the glucometers in our 
hospital are brought to the biochemistry lab for 
analysis if any inaccuracies are suspected, or if a 
device has been dropped or an accident has oc-
curred. The control and method comparison pro-
cedures are then applied to that device alone, and 
based on the obtained results, the manager de-
cides whether the device will be removed from 
service. These procedures might explain why all of 
the glucometers tested in this study seemed to be 
so unproblematic. 
In conclusion, this study proposes a convenient 
model for the routine management and monitor-
ing of the quality of a large number of glucome-
ters used in a high-volume clinical hospital setting. 
The study provides details of how a laboratory, un-
der the leadership of a biochemistry expert, 
should check the accuracy and reliability of glu-
cometer measurements performed in professional 
medical centres. We believe global standardiza-
tion is necessary with regard to this issue.
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